Asian Paints’ sharp rally, Biocon’s biosimilar boost, and improving valuations in private banks are reshaping market sentiment, says Nuvama’s CIO Nikhil Ranka. He explains why Biocon still has 10–15% upside, why Asian Paints may consolidate, and why large private banks now look attractive despite short-term NIM pressures. Read the full market outlook and sector-wise insights.
